Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID-19 Pandemic
Amgen Provides Update on its Clinical Activities and Medicine Supply Amid COVID19 Pandemic
Shots:
- Amgen anticipates no disruption in its supply of medicines for patients across the globe due to COVID-19 and is expected to have no shortage of its therapies
- The company has temporarily paused the enrollment/screening in clinical studies to ensure the safety of subjects or integrity of data during a pandemic
- Amgen reported that P-II study of AMG 510 for NSCLC, P-III study of Tezepelumab for Asthma in collaboration with AstraZeneca and P-III study of omecamtiv mecarbil for HF in collaboration with Cytokinetics are all fully enrolled, and does not anticipate any delays in obtaining results
Click here to read full press release/ article | Ref: Amgen | Image: Amgen